CONTEXT: Virtual ASCO presentation of a retrospective chart review on prostate cancer treatments.
IMPACT: Medium
READ TIME: 2 mins
Quality Level Mean [1 – 10]: 8
1. “Results from a study presented at the virtual 2021 ASCO Genitourinary Cancers Symposium highlight the importance of considering safety and tolerability of second-generation androgen receptor inhibitors during treatment decision-making for prostate cancer.”
2. “Apalutamide and enzalutamide are second generation androgen receptor inhibitors approved for the treatment of non-metastatic castration-resistant prostate cancer in the United States.”
3. “A representative subset of patients, experiencing at least 1 AE for either apalutamide (n = 125) or enzalutamide (n = 125), were selected randomly from the initial cohort to describe the management of AEs.”
4. ““This real-world study highlights the clinical and resource use burden of AEs among nmCRPC patients treated with apalutamide and enzalutamide,” concluded study authors.”
5. “—Janelle Bradley. Jiang S, Varghese D, Appukkuttan S. Frequency, management, and resource use of adverse events (AEs) in nonmetastatic castrate-resistant prostate cancer (nmCRPC) patients receiving apalutamide or enzalutamide: A real-world study.”